Isotretinoïne Doc

Isotretinoin, the active ingredient in Isotretinoïne Doc, is a retinoid presented as an oral formulation for oral use. It is indicated for the treatment of severe nodular acne and recalcitrant acne vulgaris in patients who have not responded to conventional therapies. The medication works by targeting the skin's sebaceous glands to reduce oil production and inflammation.

GNH USA supplies Isotretinoïne Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isotretinoin is a systemic retinoid used in the management of severe acne conditions.

Severe nodular acne: reduces lesion count and prevents scarring. Recalcitrant acne vulgaris: achieves clearance of persistent inflammatory lesions.

Isotretinoin may cause a range of adverse reactions. Patients should be monitored regularly for both common and serious events.

Common Side Effects: - Dry skin and mucous membranes - Cheilitis (cracked lips) - Dry eyes or irritation - Nasal dryness leading to epistaxis - Photosensitivity to sunlight - Elevated triglyceride levels

Serious or Rare Side Effects: - Severe liver enzyme elevation - Pancreatitis - Depression, suicidal ideation, or mood changes - Teratogenic effects causing fetal malformations - Pseudotumor cerebri (increased intracranial pressure) - Severe hypervitaminosis A manifestations

Before initiating therapy, clinicians should evaluate patient history and conduct baseline laboratory tests. - Pregnancy contraindication: avoid use in pregnant women due to high teratogenic risk. - Contraception requirement: effective birth control must be used during treatment and for one month after cessation. - Liver function monitoring: perform periodic liver enzyme tests. - Lipid profile monitoring: check serum triglycerides regularly. - Avoid concurrent vitamin A supplementation: may increase toxicity. - Store below 25°C: keep in the original pack, protect from moisture.

Isotretinoin can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Tetracycline antibiotics: increased risk of intracranial hypertension. - Vitamin A supplements: additive risk of hypervitaminosis A.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may reduce isotretinoin efficacy. - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may lower drug levels. - Azole antifungals (e.g., ketoconazole): may raise isotretinoin concentrations.